ReviewCurrent oncology reports2025
"Monocytes in B-Cell Malignancies: Their Role in Disease Progression and Therapy Resistance".
Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewAlthough current treatments have improved outcomes in B-cell malignancies, therapy resistance remains a major challenge and is often driven by the tumor microenvironment. The purpose of this review was to assess the roles of monocytes and monocyte-derived cells in leukemia and lymphoma and to evaluate the potential of therapies targeting these populations. RECENT
findingsRecent studies indicate that monocytes and monocyte-derived cells are associated with poor prognosis, therapy resistance, and treatment-related side effects in B-cell malignancies. These cells can suppress anti-tumor immunity, support malignant cell survival, and impair therapeutic efficacy. Strategies to deplete or reprogram these populations have shown promise in restoring immune function and enhancing the effectiveness of current treatments. Targeting suppressive monocyte-derived populations offers a promising strategy to overcome therapy resistance and improve outcomes in B-cell malignancies. Modulating these cells may reduce relapses, enhance treatment responses, and provide a foundation for the development of next-generation immunotherapies. Nevertheless, further studies are needed to better define the immunosuppressive and therapy-relevant subpopulations in specific diseases, which will be critical to translating these strategies into effective clinical interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.